Literature DB >> 25032896

A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.

Hristo P Varbanov1, Simone Göschl, Petra Heffeter, Sarah Theiner, Alexander Roller, Frank Jensen, Michael A Jakupec, Walter Berger, Mathea Sophia Galanski, Bernhard K Keppler.   

Abstract

A novel class of platinum(IV) complexes of the type [Pt(Am)(R(COO)2)2], where Am is a chelating diamine or two monodentate am(m)ine ligands and R(COO)2 is a chelating dicarboxylato moiety, was synthesized. For this purpose, the reaction between the corresponding tetrahydroxidoplatinum(IV) precursors and various dicarboxylic acids, such as oxalic, malonic, 3-methylmalonic, and cyclobutanedicarboxylic acid, was utilized. All new compounds were characterized in detail, using 1D and 2D NMR techniques, ESI-MS, FTIR spectroscopy, elemental analysis, TGA, and X-ray diffraction. Their in vitro cytotoxicity was determined in a panel of human tumor cell lines (CH1, SW480 and A549) by means of the MTT colorimetric assay. Furthermore, the lipophilicity and redox properties of the novel complexes were evaluated in order to better understand their pharmacological behavior. The most promising drug candidate, 4b (Pt(DACH)(mal)2), demonstrated low in vivo toxicity but profound anticancer activity against both the L1210 leukemia and CT-26 colon carcinoma models.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25032896      PMCID: PMC4351917          DOI: 10.1021/jm500791c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

1.  Advances in platinum chemotherapeutics.

Authors:  Benjamin W Harper; Anwen M Krause-Heuer; Maxine P Grant; Madhura Manohar; K Benjamin Garbutcheon-Singh; Janice R Aldrich-Wright
Journal:  Chemistry       Date:  2010-06-25       Impact factor: 5.236

Review 2.  Chromatographic retention parameters in medicinal chemistry and molecular pharmacology.

Authors:  Antoni Nasal; Danuta Siluk; Roman Kaliszan
Journal:  Curr Med Chem       Date:  2003-03       Impact factor: 4.530

3.  Cationic intermediates in oxidative addition reactions of Cl2 to [PtCl2(cis-1,4-DACH)].

Authors:  Nicola Margiotta; Rosa Ranaldo; Francesco P Intini; Giovanni Natile
Journal:  Dalton Trans       Date:  2011-11-07       Impact factor: 4.390

4.  Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design.

Authors:  Rodney P Feazell; Nozomi Nakayama-Ratchford; Hongjie Dai; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2007-06-15       Impact factor: 15.419

Review 5.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

6.  Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes.

Authors:  Giuseppe Ermondi; Giulia Caron; Mauro Ravera; Elisabetta Gabano; Sabrina Bianco; James A Platts; Domenico Osella
Journal:  Dalton Trans       Date:  2012-12-21       Impact factor: 4.390

7.  Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.

Authors:  S R Pestieau; J F Belliveau; H Griffin; O A Stuart; P H Sugarbaker
Journal:  J Surg Oncol       Date:  2001-02       Impact factor: 3.454

8.  Synthesis, characterization, and properties of a group of platinum (IV) complexes.

Authors:  R J Brandon; J C Dabrowiak
Journal:  J Med Chem       Date:  1984-07       Impact factor: 7.446

9.  Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination.

Authors:  Michael R Reithofer; Seied M Valiahdi; Michael A Jakupec; Vladimir B Arion; Alexander Egger; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2007-11-22       Impact factor: 7.446

10.  Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.

Authors:  Hristo P Varbanov; Seied M Valiahdi; Christian R Kowol; Michael A Jakupec; Mathea S Galanski; Bernhard K Keppler
Journal:  Dalton Trans       Date:  2012-12-21       Impact factor: 4.569

View more
  7 in total

1.  Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands.

Authors:  Yosra Benabdelouahab; Laura Muñoz-Moreno; Malgorzata Frik; Isabel de la Cueva-Alique; Mohammed Amin El Amrani; María Contel; Ana M Bajo; Tomás Cuenca; Eva Royo
Journal:  Eur J Inorg Chem       Date:  2015-04-09       Impact factor: 2.524

2.  A Theoretical Study on the Medicinal Properties and Eletronic Structures of Platinum(IV) Anticancer Agents With Cl Substituents.

Authors:  Xiaoyang Yan; Hongwei Gao
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

3.  Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.

Authors:  Sarah Theiner; Christoph Kornauth; Hristo P Varbanov; Markus Galanski; Sushilla Van Schoonhoven; Petra Heffeter; Walter Berger; Alexander E Egger; Bernhard K Keppler
Journal:  Metallomics       Date:  2015-04-09       Impact factor: 4.526

4.  Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.

Authors:  Sarah Theiner; Hristo P Varbanov; Markus Galanski; Alexander E Egger; Walter Berger; Petra Heffeter; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2014-11-21       Impact factor: 3.358

5.  An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.

Authors:  Josef Mayr; Petra Heffeter; Diana Groza; Luis Galvez; Gunda Koellensperger; Alexander Roller; Beatrix Alte; Melanie Haider; Walter Berger; Christian R Kowol; Bernhard K Keppler
Journal:  Chem Sci       Date:  2016-12-15       Impact factor: 9.825

6.  Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies.

Authors:  Heiko Geisler; Julia Westermayr; Klaudia Cseh; Dominik Wenisch; Valentin Fuchs; Sophia Harringer; Sarah Plutzar; Natalie Gajic; Michaela Hejl; Michael A Jakupec; Philipp Marquetand; Wolfgang Kandioller
Journal:  Inorg Chem       Date:  2021-06-11       Impact factor: 5.165

7.  The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo-A Comparison of O,O-, S,O-, and N,N-Chelate Effects.

Authors:  Iker Berasaluce; Klaudia Cseh; Alexander Roller; Michaela Hejl; Petra Heffeter; Walter Berger; Michael A Jakupec; Wolfgang Kandioller; Michael S Malarek; Bernhard K Keppler
Journal:  Chemistry       Date:  2019-11-19       Impact factor: 5.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.